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Staphylococcus aureus asymptomatically colonises the nose of about 20% of the healthy population, but can also cause 
mild to severe infections. Antibiotic treatment of these infections is not always successful, resulting in substantial therapy 
failure. Therefore, more effective treatment is urgently required. Among alternative antimicrobial intervention strategies, 
both active and passive immunisation in the prevention and cure of S. aureus infection is investigated in experimental 
animals and patients. The translational value of animal studies is determined by a proper selection of bacterial target, 
infection model, treatment modalities, and outcome parameters. In experimental animals, various infection models are 
described for studying the efficacy of immunisation. Most of these studies focussing on a broad range of bacterial targets 
were successful in prevention, reduction or cure of infection. The efficacy of immunisation focused on a limited number of 
bacterial targets was also investigated in S. aureus infected patients or individuals that are at high risk for S. aureus 
infection. In these studies, final conclusions on the efficacy of immunisation cannot be drawn.  
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1. Introduction 
About 20% of the healthy population persistently carries S. aureus in their nose [1]. Carriage of S. aureus is 
asymptomatic, although it can also cause infection. S. aureus infection represents a serious burden to global public 
health, particularly with respect to infections in healthcare-related settings. In this respect, S. aureus is not only 
associated with serious infections such as surgical wound infections and pneumonia, but also with serious invasive 
disease, including sepsis, which may result in endocarditis, osteomyelitis and meningitis [2]. Further, MRSA has now 
become prevalent within hospitals, leading to a significantly increased risk of mortality and increased length of stay for 
hospitalised patients [3]. Alarmingly, recent years have also witnessed the spread of resistant staphylococci outside the 
healthcare setting, with the prevalence of community-acquired MRSA now increasing [4]. Even more alarming is the 
emergence of vancomycin- and mupirocin-resistant S. aureus strains, which represent a major threat to the control of S. 
aureus infections within both the hospital and community setting [5,6]. These worrying developments indicate that 
there is an urgent need to develop novel long-lasting anti-staphylococcal therapies to enhance, or even replace, current 
antibiotic-related therapies. Among alternative, non-antibiotic-related, antimicrobial intervention strategies, both active 
and passive immunisation in the prevention and cure of S. aureus infection is investigated in experimental animals and 
patients. These novel treatment strategies need to be thoroughly evaluated before they can be applied within the clinical 
setting. Although in vitro assays provide a hint of the efficacy of both active and passive immunisation strategies 
against S. aureus infection, they may be inadequate or even misleading for the prediction of actual in vivo efficacy. 
Therefore, studies in vivo are of high importance. When utilizing in vivo animal models, a well-planned experimental 
study design is essential in order to generate data with a high translational value for patients using a minimum input of 
animals. In this respect, a proper selection of the bacterial target, infection model, treatment modalities, and outcome 
parameters is crucial. In this chapter, an overview of the study design as well as the results obtained with immunisation 
in experimental animals and clinical studies is provided. 
2. Bacterial target 
Selection of the S. aureus target is the first and probably most essential step in designing a study on immunisation as 
antimicrobial strategy. The criteria to which the ideal target should meet need to be defined. 
 Immunogenicity of the bacterial target is required to be successful in immunisation studies in S. aureus infection. 
This means that antibodies against the target are expected to be produced. An indication which S. aureus antigen should 
be targeted with immunisation is provided by studies comparing anti-staphylococcal antibody levels in S. aureus 
carriers or S. aureus infected patients with non-carriers or non-infected patients, respectively. Antibodies against these 
antigens may play important roles in S. aureus colonisation and infection. For example, IgG against SEA and TSST-1 is 
elevated in carriers compared to non-carriers [7], while IgG against glucosaminidase, HlgB, LukF-PV, SA0688, SCIN, 
SSL1, and SSL5 are higher in patients with S. aureus bacteraemia than in non-infected patients [8].  
 Although a broad panel of S. aureus antigens appears to be immunogenic, these antibodies are not always sufficient 
to eliminate S. aureus from the nose of S. aureus carriers [7]. Moreover, the anti-staphylococcal antibodies present in 
healthy individuals do not prevent them from getting infected with S. aureus as carriers of S. aureus have higher anti-
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staphylococcal antibody levels [7] and also a higher chance on developing S. aureus infections than non-carriers [9]. 
This might support the exclusion of these antigens as target for immunisation as antimicrobial strategy. 
 Immunisation based on more than one S. aureus antigen as target is expected to be more valuable than immunisation 
focusing on a single antigen, as each S. aureus carrier or S. aureus infected patient develops a unique immune response 
against different S. aureus antigens. Another reason for the selection of multiple targets for immunisation strategies is 
the presence of functional redundancy. S. aureus produces many antigens, of which some have similar or comparable 
functions. When one of these antigens is absent in a S. aureus strain, another antigen will take over this function. 
 S. aureus targets without sequence variation in the immunoglobulin binding domain should be preferred above 
targets with genetic variation. This increases the chance that the variable region of the antibodies, either induced by 
active immunisation or administered as passive immunisation, is able to bind to the epitope on the S. aureus target, and 
will enhance a successful treatment of the S. aureus infection. As McCarthy and Lindsay [10] showed sequence 
variation in 25 surface bound S. aureus proteins as well as in 13 secreted proteins amongst the 58 S. aureus genomes 
studied, they emphasise that immunisation as antimicrobial strategy should contain (antibodies against) cocktails of 
antigens representing all variants of the S. aureus targets. 
 A polyvalent strategy may not be necessary when the S. aureus target is conserved on all S. aureus strains. Choosing 
a conserved S. aureus target will enhance the success rate of immunisation as antimicrobial strategy in infections which 
are caused by a wide variety of S. aureus strains. This is of main importance as the S. aureus strains causing infections 
in patients are very heterogenous [8,11]. Ziebandt et al [11] observed that 7 extracellular proteins were produced by all 
17 clonally different S. aureus strains (IsaA, Lip, LytM, Nuc, SA0620, SA2097, and SA2437). A further 9 proteins 
(Aur, Geh, GlpQ, α-toxin, HlgB, SA0570, SA1812, SspA and SspB) were identified in at least 80% of these strains. 
Especially the 7 proteins are interesting targets for monovalant immunisation strategies towards all S. aureus strains. 
 Another consideration that has to be taken into account when selecting the bacterial target for immunisation as 
antimicrobial strategy is that the selected target needs to be accessible for antibodies enabling binding of antibodies to 
the target. To this aim, the target needs to be exposed on the bacterial surface, or has to be excreted. In addition, target 
expression during S. aureus infection is needed.  
3. Treatment modalities 
Important choices concerning treatment modalities are active or passive immunisation as well as dosing. 
3.1. Active or passive immunisation 
In active immunisation, also called vaccination, antigenic material (vaccine) is administered before infection, and aims 
for stimulation of the immune system to develop adaptive immunity. This vaccine may consist of intact, but inactivated 
or attenuated S. aureus cells, or purified components of the bacterium. In case the target is immunogenic, active 
immunisation will result in an antibody response directed against the target. Moreover, the antigen will elicit an effector 
T cell response.  
 The use of an adjuvant in active immunisation is highly preferred in order to induce inflammation at the injection 
site, which will enhance the immune response. It is known that immunisation with purified proteins without adjuvant 
leads to a poor immune response. In addition, adjuvants cause soluble protein antigens to aggregate and precipitate 
forming particles, which will facilitate their efficient uptake by antigen-presenting cells and reduce the rate at which the 
antigen is cleared from the system. Various adjuvants are used in active immunisation studies concerning S. aureus. 
CFA is commonly used. This is an emulsion of killed mycobacteria and mineral oil into which antigens are vigorously 
mixed. In experimental animals, the use of CFA should be limited because of its painful reaction and potential for tissue 
damage. IFA only contains the mineral oil, and is often used as adjuvant in booster immunisations after CFA as 
adjuvant in the first immunisation. Next to CFA/IFA, Ribi adjuvant, AAHSA, cholera toxin, toxoids, saponin, Abisco-
100 and alum are also described as adjuvants in active immunisation against S. aureus infections in experimental 
animals. 
 In passive immunisation, antibodies directed against the bacterial target are injected into the body. Passive 
immunisation can be administered before infection (prophylactic treatment) or after infection (therapeutic treatment). 
Although passive immunisation will provide a quick response, the benefit is short-lasting as the antibodies once injected 
will naturally be broken down. In passive immunisation, the type of antibodies used is of importance. Antibodies can be 
monoclonal or polyclonal, directed against one or more epitopes of the target, respectively. Next, antibodies may be 
derived from human origin in order to be directly applicable in the clinical setting, or they may have an animal origin, 
with better chances for protective efficacy in an animal model. 
3.2. Dosing 
All kinds of dosing schedules and routes of administration are used in the various studies on active and passive 
immunisation as antimicrobial strategy.  
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 In studies concerning active immunisation in experimental models, animals are immunised at least two times, and in 
one study even ten times. Booster immunisations after the primary exposure may lead to long-lasting immunity through 
activation of immunological memory cells. Time intervals between two consecutive injections vary as well. In most 
studies, this interval is 1-2 weeks. Immunisation injections are mostly given via the s.c. or i.m. route, while i.n., i.p., i.v., 
and i.t. injections are also described. In some studies, two routes of administration are combined. In general, dose-
finding is necessary for each target and route of administration. In contrast to the animal studies, in clinical studies 
active immunisation is performed only once, via the i.m. route. 
 In passive immunisation studies in most experimental models, animals are immunised with a single prophylactic gift 
of antibodies. This gift is administered 2 days to several hours before infection. In only a few passive immunisation 
studies, therapeutic treatment is applied. The antibodies are mainly administered via the i.p. route, while i.v. 
administration is also described. Again, dose-finding is necessary. In contrast to the animal studies, in clinical studies 
passive immunisation is performed via the i.v. route, either as prophylactic or as therapeutic treatment. Number of 
immunisations range from a single gift to immunisation twice daily. 
4. Outcome parameters 
To monitor the course of infection and to assess the efficacy of immunisation, relevant outcome parameters are of high 
importance.  
 Overall, in experimental animal studies, clinical signs of illness, including body temperature, behaviour, and 
appearance are monitored over time. In models of skin infection, also the lesion size over time is monitored. In lethal 
infection models, disease progression score over time is assessed. In all models, after dissection of the animals, bacterial 
load in blood and relevant organs may be determined. It always needs to be confirmed that the S. aureus isolate 
recovered from the infected animals is identical to the S. aureus isolate inoculated. 
 In clinical studies, next to clinical signs of illness, prevention of (relapse of) S. aureus infection is an important 
outcome parameter to assess the efficacy of immunisation as antimicrobial strategy. 
5. Experimental animal studies 
Regarding the design of in vivo studies in experimental animals and the interpretation of the results obtained, one has to 
realise that animal models of infection only mimic the infection in humans, mainly because the infective dose used in 
artificially induced infections in animals is different from the naturally acquired infection in patients. At the same time, 
animal models – provided well characterised – are needed and accepted as well for studying the potential efficacy of 
novel treatment strategies, as they provide the unique opportunity to study treatment efficacy under similar conditions 
of intensity and duration of infection. Uniform groups of patients are difficult to obtain because of differences in 
underlying clinical conditions.  
 A proper experimental design when performing animal studies is always required to generate maximum results with 
a minimum input of animals. Next to choice of bacterial targets, treatment modalities and outcome parameters, proper 
selection of the infection model is of main importance. 
5.1. Infection model 
The experimental infection model is characterised by the animal species, type of infection, and the infecting S. aureus 
strain used. Relevant choices have to be made in light of the research question that needs to be answered, and will be 
discussed. 
5.1.1. Animal species 
In experimental models of S. aureus infection, a variety of animal species are used. A prerequisite of the selected 
animal species is that it has to be susceptible to S. aureus. 
 Mice are often used as experimental animals, being relatively inexpensive compared to other animal species, easy to 
maintain and easy to handle. Moreover, much is known about mouse genetics and immunology, and knock-out mouse 
strains are available. In addition, immunologic reagents applicable in mouse tissues are widely available.  
 In experimental S. aureus studies, next to different strains of mice, also rats, cotton rats, rabbits, sheep, cattle and 
rhesus macaques are used for evaluation of the efficacy of active or passive immunisation. The cotton rat has been 
described as a good model for S. aureus nasal colonisation as nasal histology of cotton rats is comparable to that of 
humans. Moreover, pretreatment with antibiotics, being required to establish nasal colonisation in mice, is not needed in 
cotton rats [12]. In contrast to rodents and rabbits, sheep and cattle may be naturally colonised and infected by S. 
aureus. This is interesting for studying the potential efficacy of treatment. However, these S. aureus strains are 
genetically different from those found in humans [13]. Rhesus macaques, being naturally colonised by S. aureus in their 
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noses are the most suitable experimental animals [14]. However, while rhesus macaques are genetically more related to 
humans than cotton rats, sheep and cattle are, ethical issues limit the use of large groups of macaques.  
 In addition to the selection of the animal species, the microbial status of the experimental animal needs attention. 
Microbiological standardisation is an important tool to achieve reproducible animal experiments. Most commercial 
suppliers of experimental animals have a health monitoring program based on the FELASA Recommendations [15]. 
The supplier lists the organisms that are not present in the experimental animal. In this respect, animals with a SPF 
status are not tested for the presence of S. aureus, while those with a SOPF status are free of S. aureus. In order to 
maintain the microbial health status in the facility were the animal experiments are performed, it is important that 
animals are housed in individually ventilated cages. Disinfected gloves should be worn when handling these animals, to 
prevent transmission of human colonising S. aureus strains to the animals. 
5.1.2. Infection type 
S. aureus can cause a variety of infections [9], ranging from mild skin infections to more severe infections like arthritis, 
endocarditis and sepsis, as shown in Fig. 1. Many types of infection models are described, some more extensively 
characterised than others. For each research question, the most suitable experimental infection should be selected, and 
clinically relevant infections that urgently need alternative treatment should be preferred. The following models have 
been published for studying immunisation as antimicrobial strategy in S. aureus infections: 
 
- nasal carriage 
- skin infection, wound infection 
- keratitis 
- mastitis 
- catheter-related infection 
- endocarditis 
- renal abscess 
- pneumonia 
- septic arthritis 
- bacteraemia 
- sepsis 
- shock 
 5.1.3. Infecting strain 
Many different S. aureus strains were used among which clinical isolates as well as sequenced strains. Originally, 
sequenced strains were clinical isolates as well, but they are passaged in vitro for many times. The choice of S. aureus 
strain depends on the research question. 
 As bacterial strains may lose virulence by in vitro passage, animal passage of the infecting strains is needed to 
maintain virulence of the S. aureus strain.  
6. Results of immunisation in experimental infection models 
Numerous studies in animal models are published concerning immunisation against S. aureus infections, including a 
wide range of bacterial targets and both active and passive immunisation. Most studies concentrate on a specific 
infection model, and the experimental approach in these studies is summarised in Table 1. 
6.1. Nasal carriage 
In this infection model, mice or cotton rats are i.n. challenged with S. aureus. To assess the efficacy of immunisation, 
noses are surgically removed and homogenised to determine numbers of viable S. aureus. 
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Fig. 1 S. aureus can cause a wide range of infections. Figure adapted from Wertheim et al [9]. 
 
 Active immunisation with IsdA, IsdH, FmtB, SA2666 or the glucosaminidase domain of Atl was studied by Clarke et 
al [16]. Only immunisation with IsdA or IsdH protected against nasal carriage.  
 Schaffer et al [17] investigated whether active immunisation with ClfB resulted in lower S. aureus load in the nose of 
mice. While s.c. immunisation with ClfB resulted in lower S. aureus colonisation levels, i.n. immunisation with ClfB 
did not protect mice against nasal colonisation. Passive immunisation targeting both CP5 and ClfB reduced the bacterial 
load in the nose of mice as well, as observed by Pozzi et al [18].  
6.2. Skin infection, wound infection 
For the model of skin infection, mice are challenged with S. aureus via the i.d. or s.c. route. In some cases, bacteria are 
mixed with dextran beads to promote abscess formation. Efficacy parameters include body weight changes, size of the 
abscess, hyperaemia (increased blood flow), skin injury, and viable S. aureus load in the abscess. 
 Kennedy et al [19] studied both active and passive immunisation focused on α-toxin in a murine model of skin 
infection. Both immunisation strategies resulted in reduction of abscess size. Passive immunisation targeting α-toxin 
was also studied by Foletti et al [20]. They also observed a reduced abscess size and a reduction of the bacterial burden 
in the abscess. Active immunisation with LukF-PV or LukS-PV was studied by Brown et al [21]. While s.c. 
immunisation protected mice against body weight loss, i.n. immunisation was not effective. 
 Three studies used S. aureus mixed with dextran beads for infection. Park et al [22] infected mice with S. aureus, and 
at the same time, mice were passively immunised targeting AIP-4. This passive immunisation reduced hyperaemia and 
skin injury. In the study of Balaban et al [23], mice were actively immunised with RAP. This immunisation reduced the 
incidence of cutaneous lesions, as well as the lesion size. Pozzi et al [18] passively immunised mice targeting PNAG 
and α-toxin; CP5 and ClfB; or CP8 and IsdB. These immunisations resulted in a reduction in bacterial load in the 
abscesses. 
 A model of wound infection in mice was described by Schennings et al [24]. A full thickness wound was punched 
out through the skin, which was subsequently infected with S. aureus. Mice were actively immunised with Eap, ClfA, 
and Efb. This reduced the number of infected wounds. 
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6.3. Keratitis 
One study, by Hume et al [25], investigated both active and passive immunisation targeting α-toxin in a keratitis model. 
In this infection model, rabbits are infected with S. aureus in the cornea. Both immunisation strategies targeting α-toxin 
protected against cornea erosion. 
6.4. Mastitis 
Mice, rabbits, sheep or cattle are challenged with S. aureus in their mammary glands. Prevention of mastitis is the 
parameter to assess efficacy of immunisation. 
 In the study of Adlam et al [26], rabbits were actively immunised with α-toxin, resulting in prevention of mastitis.  
 Active immunisation with SEC was studied by Chang et al [27] in a mastitis model in cattle. Immunisation prevented 
mastitis in lactating cattle.  
 Active immunisation of cattle with whole, inactivated S. aureus was investigated by Nordhaug et al [28], resulting in 
a reduced incidence of spontaneous S. aureus mastitis. Leitner et al [29] actively immunised cows with killed S. aureus 
strains, and showed that reduction of the number of infected cows was obtained. 
 FnbpA was the target for both active and passive immunisation of mice in the studies of Mamo et al [31,32]. Both 
ways of immunisation prevented mastitis.  
 Tuchscherr et al [33] passively immunised mice targeting ClfA, CP5, or CP8, resulting in reduction of the S. aureus 
load in the infected mammary glands.  
 Watson [30] used a mastitis model in sheep. In this study, animals were actively immunised with killed cells of S. 
aureus, which resulted in a decline of mastitis. 
6.5. Catheter-related infection 
For the catheter-related infection model, mice or rats are used. A central venous catheter is surgically implanted. After 
this surgery, S. aureus is inoculated i.v. or via the catheter. Bacterial load on the catheter and in blood is determined to 
assess the efficacy of immunisation. In one study also the S. aureus load in liver, lung, spleen and kidneys is used as 
outcome parameter.  
 Passive immunisation targeting IsdB was studied by both Brown et al [34] and Ebert et al [35], in models in mice 
and rats. Brown et al observed a higher number of culture-negative catheters in mice. In the study of Ebert et al, passive 
immunisation targeting IsdB was successful as well: a reduction of bacterial load in blood and on the catheter was 
observed in rats. 
 In a study of Lorenz et al [36], IsaA was the target for passive immunisation in their model in mice. This resulted in a 
lower bacterial load in the kidneys, while the S. aureus load on the catheter was not reduced.  
6.6. Endocarditis 
In the endocarditis model, rats or rabbits are used. A catheter is introduced via the right carotid artery into the left 
ventricle, touching the aortic valve. S. aureus is inoculated via the i.v. or i.p. route. Efficacy parameters include the 
staphylococcal load on the heart valves and the attached vegetations, in blood and in kidneys. 
 Schennings et al [37] studied active immunisation of rats with Fnbp or collagen binding protein. While active 
immunisation with Fnbp reduced the bacterial load on heart valves and attached vegetations, immunisation with 
collagen binding protein did not. 
 Vernachio et al studied the efficacy of IGIV from plasma donors with elevated levels of anti-ClfA antibody. In their 
first study [38], rabbits were treated with this IGIV in addition to vancomycin treatment. This resulted in a reduction of 
bacteraemia. When in a second study [39], this IGIV was tested alone in the same infection model, a lower bacterial 
load on cardiac valve vegetations and in blood was obtained. 
 CP5 was the target selected for immunisation in studies by Lee et al [40] and Nemeth and Lee [41] in rats. Lee et al 
studied passive immunisation, while in the study of Nemeth and Lee, rats were either actively immunised with killed S. 
aureus cells expressing CP5, or passively immunised. Whereas Lee et al observed a lower prevalence of endocarditis in 
immunised rats [40], this was not observed in the study by Nemeth and Lee [41]. Next to passive immunisation 
targeting CP5, Nemeth and Lee also studied passive immunisation targeting teichoid acid. This strategy did not protect 
against staphylococcal endocarditis. 
 Active immunisation of rabbits with killed whole cell S. aureus was studied by Greenberg et al [42]. This did not 
result in reduction of the incidence of endocarditis or renal abscesses. 
 Rennermalm et al [43] published a variation on the catheter-related infection model: a combined 
arthritis/endocarditis model. In this model, rats are i.v. challenged with S. aureus, and a corticosteroid is injected into 
the mandibular joint resulting in septic arthritis in the joint. After a week, animals are catheterised to induce 
endocarditis. Animals were actively immunised with FnbpB, which did not protect rats against the development of 
arthritis, but reduced the bacterial load on aortic valves as well as in the kidneys. 
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6.7. Renal abscess 
Mice are used for the renal abscess model. S. aureus is inoculated i.v., and to assess the efficacy of immunisation, the 
kidneys are removed to determine the bacterial load and to study histopathology. 
 Stranger-Jones et al [45] actively immunised mice with IsdA, IsdB, SdrD and/or SdrE. While immunisation with 
individual antigens did not protect against S. aureus challenge, the combined vaccine reduced the bacterial load in 
kidneys below detection level, and prevented the formation of abscesses in the kidneys.  
 Kim et al [44] studied IsdA and IsdB as targets for active immunisation in mice. Passive immunisation reduced the 
bacterial load in the kidneys as well as the number of abscesses. The size of abscesses was not reduced.  
 The group of Kim also performed a study on active immunisation with protein A in mice [46]. They observed a 
reduction in bacterial load in the kidneys, as well as smaller and less abscesses in this organ.  
 PNAG was the selected target in a study of McKenney et al [47]. Both active and passive immunisation strategies in 
mice resulted in a reduction of staphylococcal load in the kidneys. In the same study, passive immunisation targeting 
CP5 and CP8 was examined, which did not result in a reduced bacterial load in the kidneys. 
6.8. Pneumonia 
In this infection model, mice are challenged i.n. by S. aureus. Disease progression and animal survival, staphylococcal 
load in lungs and pathology of the lungs are parameters to assess the efficacy of immunisation strategies. 
 In a number of studies, immunisation focused on α-toxin was investigated. Bubeck Wardenburg et al [48] observed 
in mice that active immunisation resulted in a reduced mortality, as well as a reduced number of S. aureus in lungs and 
less pathology. Passive immunisation of mice showed similar results. Ragle et al [49] performed an almost identical 
study in mice. Results obtained were identical to those of Bubeck Wardenburg et al. Foletti et al [20] included only 
passive immunisation targeting α-toxin in their study, which completely protected mice against death. In a study of 
Pozzi et al [18], passive immunisation targeting both PNAG and α-toxin resulted in 100% survival of mice as well.  
 LukF-PV and LukS-PV were targets selected for active immunisation by Brown et al [21]. While i.n. immunisation 
protected mice against death, s.c. immunisation did not. Remarkably, passive immunisation targeting LukF-PV and 
LukS-PV, used by Bubeck Wardenburg et al [48], did not protect mice against pneumonia. 
6.9. Septic arthritis 
In the model of septic arthritis, mice are challenged i.v. with S. aureus and develop septic arthritis when untreated. 
Bacterial load in joints, degree of arthritis (assessed by clinical evaluation and histopathology) and animal survival are 
evaluated to assess the efficacy of immunisation. 
 A study by Josefsson et al [50] examined whether active and passive immunisation targeting ClfA protected mice 
against septic arthritis. Active immunisation with ClfA resulted in less severe arthritis. Passive immunisation targeting 
ClfA suppressed the development of arthritis and protected mice against septic death. 
 Nilsson et al [51] evaluated active immunisation with Cna, which resulted in less severe arthritis and improved the 
survival of mice. 
6.10. Bacteraemia 
Mice are infected with S. aureus via the i.v. or i.p. route, resulting in bacteraemia. The parameters used to assess the 
efficacy of immunisation include body weight and the S. aureus load in blood, spleen, liver, kidneys and peritoneal 
cavity. 
 Passive immunisation targeting FnbpB was studied by Rennermalm et al [43]. Immunisation resulted in less decrease 
of body weight. Rozalska and Wadström [52] passively immunised mice targeting FnbpA or FnbpB, which resulted in a 
reduction of the bacterial load in liver and peritoneal cavity, and a more rapid clearance of bacteria from blood. 
 An ABC transporter was target for passive immunisation in the study of Burnie et al [53]. This resulted in a lower 
bacterial load in spleen, liver and kidneys. 
 Passive immunisation targeting CP5 and CP8 was studied by Fattom et al [54]. This resulted in less bacteraemic 
mice. 
6.11. Sepsis 
In this model, mice are challenged with S. aureus via the i.p. or i.v. route, resulting in sepsis. Disease progression is 
scored, and parameter for effective immunisation is improved survival of animals. 
 Many targets for immunisation were studied in the sepsis model in mice. Stranger-Jones et al [45] assessed the 
efficacy of active immunisation with IsdA, IsdB, SdrD and/or SdrE. Remarkably, only the combination vaccine 
protected mice against death, while immunisation with individual antigens did not.  
 In contrast to these observations, Kuklin et al [55] and Joshi et al [56] showed that active immunisation with IsdB 
alone resulted in improved animal survival. Passive immunisation targeting IsdB improved survival of mice as well 
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[34,35,56,57]. Kim et al [44] passively immunised mice targeting IsdA or IsdB, which also protected against septic 
death. 
 Zhou et al [58] studied active immunisation with both Cna and Fnbp. This resulted in improved survival of mice. 
Nilsson et al [51] studied passive immunisation targeting Cna. This also protected mice against death.  
 SEA was selected by Nilsson et al [59] as target for active and passive immunisation. Both immunisation strategies 
improved survival of mice. The target selected for active immunisation in the study of Hu et al [60] was SEC. 
Immunisation improved animal survival.  
 Active immunisation with CP5 was studied by Fattom et al [54]. This resulted in improved mouse survival. 
 Glowalla et al [61] used hypothetical protein 2160 for active immunisation. This strategy improved the survival of 
mice.  
 A number of different research groups showed that passive immunisation targeting ClfA, PNAG, AIP-4, IsaA, or α-
toxin protected mice against septic death [20,22,36,47,62-64]. 
 Commercially available human IGIV was used by Farag et al [65]. IGIV administered via i.v. route did not protect 
mice against septic death, while i.p. administration of IGIV improved animal survival.  
6.12. Shock 
In contrast to the infection models mentioned above, in this model, rhesus macaques are used. These animals are not 
challenged with viable S. aureus, but with an aerosol of a lethal dose of SEB. Disease progression (anorexia, 
progressive depression, shock) and animal survival are outcome parameters to assess the efficacy of immunisation. 
 Lowell et al [66] actively immunised macaques with SEB. This resulted in protection against severe illness and 
death. Passive immunisation targeting SEB was studied by LeClaire et al [67]. These antibodies protected macaques 
against death. 
7. Clinical studies 
While most immunisation strategies in experimental animals have been proven to be effective in prevention, reduction 
or cure of S. aureus infection, clinical trials in humans are performed to investigate this treatment strategy. In contrast to 
studies in animals, it is always difficult to obtain uniform groups of patients in clinical trials due to variation in 
underlying diseases and in history of exposure to S. aureus. Proper definition of the patient population is of major 
importance. 
 Regarding the immunisation studies against S. aureus infection, in all patients groups S. aureus infections are highly 
prevalent. 
8. Results of immunisation in clinical Phase I and Phase II/III studies 
A limited number of bacterial targets for immunisation were studied in humans. In Phase I studies, safety, tolerability 
and immunogenicity are tested in healthy adults. In Phase II/III studies, safety, tolerability, immunogenicity and 
sometimes efficacy are studied in S. aureus infected patients or individuals that are at high risk for S. aureus infection. 
The results obtained are summarised in this way. 
8.1. Phase I studies 
For SA75®, a vaccine composed of whole killed S. aureus, a Phase I study is finished. SA75® was shown to be safe and 
immunogenic [68]. Currently, no further studies with this vaccine are running. 
 PentaStaph® is a vaccine comprising CP5, CP8, polysaccharide type 336, PVL, and α-toxin, studied in Phase I [69]. 
However, this product is currently abandoned. 
 Three other Phase I studies are ongoing. One study concerns the safety and immunogenicity of GSK Biologicals 
Staphylococcal 4-component Investigational Vaccine (GSK2392102A). Two studies assess the safety of a 4-antigen S. 
aureus vaccine (SA4Ag) or a 3-antigen S. aureus vaccine (SA3Ag). In these two studies, the effect on the presence of S. 
aureus on the skin and within the nose, throat and perineum of healthy adults is determined as well [70]. 
8.2. Phase II/III studies 
A number of Phase II/III clinical studies in S. aureus patients or individuals at high risk for S. aureus infection are 
summarised below. 
8.2.1. Patients receiving haemodialysis 
As S. aureus infection is a prominent cause of complications and death among patients receiving haemodialysis [71], 
adequate treatment to prevent these infections is needed. 
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 StaphVAX® is a vaccine containing CP5 and CP8. These polysaccharides are conjugated to nontoxic recombinant 
Pseudomonas aeruginosa exotoxin A. The vaccine was administered by a single i.m. injection. This active 
immunisation did not provide protection against S. aureus bacteraemia. In a post-hoc analysis, evaluating the 
performance of the vaccine during various shorter time periods, StaphVAX® was shown to reduce S. aureus 
bacteraemia through 40 weeks follow-up [72,73].  
 Another vaccine, containing whole killed S. aureus combined with α-toxoid, was also investigated for prevention of 
staphylococcal infection in patients receiving haemodialysis. However, no effects of active immunisation were found on 
the incidence of peritonitis, catheter-related infections, or S. aureus nasal carriage [74]. 
8.2.2. Patients undergoing cardiothoracic surgery 
Patients undergoing cardiothoracic surgery are also a group of patients that needs adequate treatment, as infections due 
to S. aureus are serious complications, resulting in substantial morbidity and mortality [75]. 
 V710® is a vaccine containing IsdB. This vaccine was administered once via the i.m. route to patients undergoing 
cardiothoracic surgery. The rate of all surgical site or invasive S. aureus infections was not reduced. This active 
immunisation strategy was associated with even higher mortality among patients who developed S. aureus infection 
[76]. 
 Currently, studies with the vaccine StaphVAX® (described in 8.2.1) concerning safety and immunogenicity in 
patients undergoing cardiothoracic surgery are running [70]. 
8.2.3. Patients undergoing orthopaedic joint surgery 
In orthopaedic patients, S. aureus accounts for the majority of surgical site infections [77]. A treatment strategy that 
provides protection during the post-operative period would address an important unmet medical need. 
 Safety and immunogenicity of the vaccine StaphVAX® (described in 8.2.1) are currently assessed in patients 
undergoing orthopaedic joint surgery [70]. 
8.2.4. Patients with bacteraemia 
S. aureus is a leading cause of both hospital- and community-acquired S. aureus bacteraemia, and the current therapy is 
often not successful [78]. More powerful treatment is needed. 
 Aurexis® (tefibazumab) is a humanised monoclonal antibody that binds to ClfA. In patients with positive S. aureus 
blood cultures, who were treated with standard antibiotic therapy, this passive immunisation was administered once via 
the i.v. route, which was well tolerated. However, the number of patients developing S. aureus bacteraemia-related 
complications that were not present at baseline or developing relapse of bacteraemia was equal in patients treated with 
Aurexis® compared to those who received placebo-treatment [79]. 
 AltaStaph® contains polyclonal antibodies from humans immunised with the vaccine StaphVAX® (described in 
8.2.1), and targets CP5 and CP8. Bacteraemic patients were passively immunised with two i.v. injections, next to 
standard antibiotic treatment. The median time to resolution of S. aureus bacteraemia was not significantly different 
between the AltaStaph® group and the placebo group. The time to hospital discharge was reduced in the AltaStaph® 
group. However, due to the small sample size, this study was not powered to show efficacy, and therefore, this passive 
immunisation strategy warrants further investigation [80]. 
8.2.5. Patients with deep-seated infection 
Treatment failure of deep-seated MRSA infections often occurs. Higher vancomycin concentrations are thought to be 
necessary. However, this results in a higher risk of nephrotoxicity [81]. Therefore, alternatives for vancomycin 
treatment are urgently needed. 
 Aurograb® is a single-chain monoclonal antibody variable fragment binding to an ABC transporter. Patients with 
deep-seated MRSA infection were passively immunised twice daily via the i.v. route, next to vancomycin. No 
additional efficacy was observed in patients treated with both antibiotics and Aurograb®, and therefore Aurograb® was 
not further developed [69,82]. 
8.2.6. Very low birth weight infants 
S. aureus is one of the most common organisms causing late onset sepsis, the leading cause of death in infants with very 
low birth weight [83]. More adequate treatment of this infection is needed to lower mortality. 
 Veronate® (INH-A21) is an intravenous immunoglobulin from donors with high levels of antibodies directed against 
ClfA. Premature infants were passively immunised with four i.v. infusions of this IGIV. Bloom et al [84] showed that 
this IGIV had potential to reduce S. aureus sepsis and mortality in this group, but statistical significance was not 
reached. In a study of DeJonge et al [85], Veronate® failed to reduce the incidence of late onset sepsis in premature 
infants. 
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 AltaStaph® (described in 8.2.4), polyclonal antibodies targeting CP5 and CP8, was applied in very low birth weight 
neonates. Passive immunisation with two i.v. infusions of AltaStaph® induced high levels of CP5 and CP8 specific 
antibodies, but rates of S. aureus bacteraemia were similar in the treatment and the placebo group. However, due to the 
small sample size, this study was not sufficiently powered to detect small differences in outcome, and therefore a study 
including more patients is needed [86].  
 Pagibaximab® is a humanised monoclonal antibody targeting LTA. Patients were immunised twice via the i.v. route. 
This antibody was shown to be safe and tolerable in very low birth weight infants [87]. Its efficacy has not been 
evaluated until now. 
9. Concluding remarks 
Antibiotic treatment of S. aureus infections is not always successful. Due to the emergence of antibiotic resistance, 
alternatives for antibiotic treatment are urgently needed. Active and passive immunisation could be alternative, non-
antibiotic related, antimicrobial intervention strategies. Various studies in animal models and humans have been 
conducted in this field. In animal models, a study design focused on a clinically-relevant infection, a proper bacterial 
target and well-considered dosing will enhance the translational value of the results obtained. 
 A range of experimental models of S. aureus infections are described to study the efficacy of active or passive 
immunisation as antimicrobial strategy. The animal models are well selected, as they represent the most common S. 
aureus infections in the clinical setting. A broad panel of S. aureus targets has been studied in these experimental 
models. Active and passive immunisation targeting these S. aureus antigens have mostly shown to be successful in 
prevention, reduction or cure of infection.  
 In contrast to the numerous studies in experimental animals, only a limited number of clinical studies in S. aureus 
infected patients or patients at high risk for S. aureus infection has been performed. In most of these clinical studies, S. 
aureus bacteraemia/sepsis is a common infectious complication, and is therefore used as outcome parameter for 
efficacy in immunisation studies.  
 Clinical Phase II/III studies have been performed focused on the bacterial targets CP5, CP8, IsdB, ClfA, ABC 
transporter, or whole cell S. aureus. Successful results were obtained in patients receiving haemodialysis, who are at 
high risk for S. aureus infection. Active immunisation with CP5 and CP8 (StaphVAX®) resulted in a reduction of S. 
aureus bacteraemia. Similar observations were obtained in the experimental S. aureus sepsis model in mice, showing 
that active immunisation with CP5 improved the survival of mice. This indicates the translational value of the results 
obtained in this experimental sepsis model in mice to the clinical setting.  
 Other studies in patients with S. aureus bacteraemia and in very low birth weight infants who are at high risk for S. 
aureus sepsis, investigating the efficacy of passive immunisation with antibodies targeting CP5 and CP8 (AltaStaph®), 
were less successful in providing protection against S. aureus bacteraemia. Lack of power because of the low sample 
size might contribute to the lack of success of immunisation. In contrast, in the experimental S. aureus bacteraemia 
model in mice, passive immunisation with antibodies targeting CP5 and CP8 has been shown to protect mice against 
bacteraemia. Based on these encouraging results in this animal model, more extended studies on the efficacy of 
AltaStaph® in patients with S. aureus bacteraemia are warranted. 
 Many  other  S. aureus  targets  have  been  selected  for  immunisation  studies  in  animal  infection  models.  In the 
experimental bacteraemia and sepsis models in mice, successful results were obtained with active or passive 
immunisation focusing on IsdA, IsdB, SdrD, SdrE, Cna, FnbpA, FnbpB, SEA, SEC, hypothetical protein 2160, ClfA, 
PNAG, AIP-4, IsaA, α-toxin, and/or ABC transporter, or whole cell S. aureus. From these bacterial targets, only IsdB, 
ClfA, ABC transporter or whole cell S. aureus were investigated in clinical Phase II/III immunisation studies. Efficacy 
was never observed in these studies. 
 Until now, in most clinical studies immunisation as antimicrobial strategy was investigated in relation to S. aureus 
bacteraemia/sepsis. Based on the successful immunisation studies in experimental animal models of other S. aureus 
infection, such as skin/wound infection, keratitis, mastitis, catheter-related infection, endocarditis, renal abscess, 
pneumonia and arthritis, studies in patients with S. aureus infections other than bacteraemia/sepsis investigating the 
efficacy of immunisation as antimicrobial strategy seem warranted. 
Abbreviations AAHSA, amorphous aluminium hydroxyphosphate sulphate adjuvant; AIP-4, autoinducing peptide 4; Atl; major 
autolysin; Aur, aureolysin; CFA, complete Freund’s adjuvant; ClfA and ClfB, clumping factor A and B; Cna, collagen adhesin; CP5 
and CP8, capsular polysaccharide 5 and 8; Eap, extracellular adhesion protein; Efb, extracellular fibrinogen binding protein; FmtB, 
factor effecting methicillin resistance; FnbpA and FnbpB, fibronectin-binding protein A and B; Geh, glycerol ester hydrolase; GlpQ, 
glycerophosphoryl diester phosphodiesterase; HlgB, γ hemolysin B; IFA, incomplete Freund’s adjuvant; IgG, immunoglobulin G; 
IGIV, immunoglobulins for intravenous use; IsaA, immunodominant staphylococcal antigen A; IsdA, IsdB and IsdH, iron-responsive 
determinant A, B and H; i.d., intradermal; i.m., intramuscular; i.n., intranasal; i.p., intraperitoneal; i.t., intratracheal; i.v., intravenous; 
Lip, lipase; LTA, lipoteichoic acid; LukF-PV and LukS-PV, leukocidin F and S; LytM, peptidoglycan hydrolase; Nuc, nuclease; 
MRSA, methicillin-resistant Staphylococcus aureus; PNAG, poly-N-acetylglucosamine; PVL, Panton Valentine Leukocidin; RAP, 
RNAIII activating protein; S. aureus, Staphylococcus aureus; s.c., subcutaneous; SEA, SEB and SEC, staphylococcal enterotoxin A, 
B and C; SCIN, staphylococcal complement inhibitor; SdrD and SdrE, serine-aspartate dipeptide repeat protein D and E; SOPF, 
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specified opportunistic pathogen free; SPF, specified pathogen free; SSL1 and SSL5, staphylococcal superantigen-like protein 1 and 
5; SspA and SspB, staphylococcus serine protease A and B; TSST-1, toxic shock syndrome toxin 1. 
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